US2019127356A1PendingUtilityA1

Substituted Chromanes and Method of Use

63
Assignee: ABBVIE SARLPriority: Oct 31, 2014Filed: Dec 19, 2018Published: May 2, 2019
Est. expiryOct 31, 2034(~8.3 yrs left)· nominal 20-yr term from priority
C07D 491/052A61K 31/353A61P 11/00C07D 407/12A61K 31/436A61K 31/5377A61K 31/36A61K 31/453C07D 417/14A61K 31/4433A61P 43/00A61P 1/00A61K 45/06A61K 31/4025C07D 413/14A61K 31/435A61K 31/397A61K 31/00C07D 405/14C07D 491/107C07D 311/58A61K 31/352
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides for compounds of formula (I) wherein R 1 , X, Y, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , m, and R″ have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A compound having the formulae: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof; 
         wherein one or more hydrogen atoms of the compound are replaced by deuterium.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.